68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
WP Fendler, M Eiber, M Beheshti, J Bomanji… - European journal of …, 2017 - Springer
The aim of this guideline is to provide standards for the recommendation, performance,
interpretation and reporting of 68 Ga-PSMA PET/CT for prostate cancer imaging. These …
interpretation and reporting of 68 Ga-PSMA PET/CT for prostate cancer imaging. These …
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
M Del Prete, FA Buteau, JM Beauregard - European journal of nuclear …, 2017 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with 177 Lu-octreotate is commonly
administered at empiric, fixed amounts of injected radioactivity (IA). This results in highly …
administered at empiric, fixed amounts of injected radioactivity (IA). This results in highly …
[HTML][HTML] Accuracy of 177Lu activity quantification in SPECT imaging: a phantom study
Background The aim of the study is to assess accuracy of activity quantification of 177 Lu
studies performed according to recommendations provided by the committee on Medical …
studies performed according to recommendations provided by the committee on Medical …
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy …
Purpose Bulky disease is an adverse prognostic factor for 177 Lu-DOTA-octreotate (177 Lu-
DOTATATE) peptide receptor radionuclide therapy (PRRT). 90 Y-DOTA-octreotate (90 Y …
DOTATATE) peptide receptor radionuclide therapy (PRRT). 90 Y-DOTA-octreotate (90 Y …
[PDF][PDF] Personalized dosimetry for 188 Re radionuclide therapies based on post-treatment SPECT/CT scans
A Celler, PL Esquinas - Int J Nucl Med Res, 2017 - core.ac.uk
Over the last three decades, Rhenium-188 (188Re) applications in Nuclear Medicine
therapies have gathered a lot of interest thanks to the favorable physical and chemical …
therapies have gathered a lot of interest thanks to the favorable physical and chemical …
High clinical and morphologic response using Y-DOTA-octreotate sequenced with Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy …
G Kong, J Callahan, M Hofman… - … Journal of Nuclear …, 2017 - search.ebscohost.com
Purpose: Bulky disease is an adverse prognostic factor for Lu-DOTA-octreotate (Lu-
DOTATATE) peptide receptor radionuclide therapy (PRRT). Y-DOTA-octreotate (Y …
DOTATATE) peptide receptor radionuclide therapy (PRRT). Y-DOTA-octreotate (Y …